


the group comprising:


, 
, and 

wherein: r is 1; Ar* is Ar-R^1*; R^1* is selected from -C(O)O-P^2, -SO_2O-P^5, -SO_2NH-P^6, -P(O)(O-P^7)$_2$, -OCH(CH_3)-C(O)O-P^2, -OCH(aryl)-C(O)O-P^2, and tetrazol-5-yl-P^4; R^{5*} is selected from -C_{0-3}alkylene-S-P^3, -C_{0-3}alkylene-C(O)NH(O-P^5), -C_{0-3}alkylene-N(O-P^5)-C(O)R^{5d}, -C_{0-1}alkylene-NHC(O)CH_2S-P^3, -NH-C_{0-1}alkylene-P(O)(O-P^7)$_2$, -C_{0-3}alkylene-P(O)(O-P^7)-R^{5e}, -C_{0-2}alkylene-CHR^{5f}-C(O)O-P^2 and -C_{0-3}alkylene-C(O)NR^{5g}-CHR^{5h}-C(O)O-P^2; P^2 is a carboxy-protecting group selected from methyl, ethyl, *t*-butyl, benzyl, *p*-methoxybenzyl, 9-fluorenylmethyl, trimethylsilyl, *t*-butyldimethylsilyl, and diphenylmethyl; P^3 is a ~~thiol-protecting group selected from ethers and esters~~ C(O)CH_3; P^4 is a tetrazole-protecting group selected from trityl and diphenylmethyl; P^5 is a hydroxyl-protecting group selected from C_{1-6}alkyl, ~~silyl groups, esters, and arylmethyl~~ trimethylsilyl, triethylsilyl, *tert*-butyldimethylsilyl, formyl, acetyl, pivaloyl, benzoyl, benzyl, *p*-methoxybenzyl, 9-fluorenylmethyl, and diphenylmethyl; P^6 is a sulfonamide-protecting group selected from *t*-butyl ~~and acyl groups~~, formyl, acetyl, phenylacetyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, benzoyl, and 4-acetoxybenzoyl; and P^7 is a phosphate-protecting group selected from C_{1-4}alkyl, aryl, chlorophenyl, and methylphenyl ~~and substituted aryl~~; and salts thereof.


35. The compound of Claim 1 for use as a medicament.

36. Use of a compound of Claim 1 in the manufacture of a medicament for the treatment of hypertension or heart failure.

37. Use of a compound of Claim 1 in the manufacture of a medicament for antagonizing an angiotensin II type 1 receptor in a mammal.

38. Use of a compound of Claim 1 in the manufacture of a medicament for inhibiting a neprilysin enzyme in a mammal.

39. The compound of Claim 1, wherein the compound is



, wherein R^{1a} = H; R^{5a} = H.